Clinical Trial Update: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase III open-label study comparing maintenance lurbinectedin plus atezolizumab vs atezolizumab alone in extensive-stage small-cell lung cancer, status active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Small-Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-29